ResearcherJilin UniversityNo recent work listed

Changwen Ning

Verified by OpenAlex author ID (good confidence)As of 10 November 2026

Matched on OpenAlex author ID A5026401594.

Their work

Papers: 1 (first author 1, last author 0)
Trials: 0
Grants: 0
Collaborators: 4

Papers, trials and grants by year

2017: 1 paper

Papers 1

Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer. First author DOI 10.18632/oncotarget.17869 ↗

Closest collaborators

The 4 strongest of 4 ranked by shared papers, trials and grants, with recent and small-team work weighing most.

Guan Wang · 1 shared paper, 2017
- Paper Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of … DOI 10.18632/oncotarget.17869 ↗
Shuang Liu · 1 shared paper, 2017
- Paper Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of … DOI 10.18632/oncotarget.17869 ↗
Asfar Sohail Azmi · 1 shared paper, 2017
- Paper Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of … DOI 10.18632/oncotarget.17869 ↗
Yubin Ge · 1 shared paper, 2017
- Paper Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of … DOI 10.18632/oncotarget.17869 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.